Effects of shark cartilage polysaccharides on the secretion of IL-6 and IL-12 in rheumatoid arthritis

被引:3
|
作者
Yang Chuan-Ying [1 ]
Zheng Lei [1 ]
机构
[1] Shandong Traff Hosp, Inst Pharm, Jinan, Peoples R China
关键词
Glycosaminoglycans; autoimmune disease; lymphokine; inflammatory; INTERLEUKIN-6; CYTOKINES; EXTRACT;
D O I
10.3109/13880209.2012.684692
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Context: Rheumatoid arthritis (RA) is a chronic inflammatory disease caused by inflammation of the synovial membrane, leading to articular cartilage destruction. Shark cartilage polysaccharide (SCP) is a biodegradable, biocompatible, nontoxic, non-immunogenic and non-inflammatory polysaccharide that may be used in treating RA. Objective: The anti-RA activities of SCP given orally to rats are investigated here for the first time. Materials and methods: SCP treatment group were administered with SCP-1, SCP-2 in the dosage of 9 mg/day for 24 days. The effect of SCP-1 and SCP-2 on the body weight, paw swelling, morphological changes of ankle and IL-6, IL-12 secretion in RA rats are examined. Results: On day 24, there were no obvious differences in BMI between positive, SCP-1 and SCP-2 group. The swelling degree of SCP-1 and SCP-2 group was less serious than model group. X-ray revealed that SCP-1, SCP-2 group owned normal joint alignment and more smooth and tidy articular surface. The SCP-1 and SCP-2 have inhibitory effect on IL-6 (430.3 +/- 25.6 pg/mL, 439.1 +/- 35.9 pg/mL) and IL-12 (63.9 +/- 20.1 pg/mL, 64.9 +/- 14.1 pg/mL) secretion, which showed significant differences with model group (612 +/- 72.3 pg/mL, 230.1 +/- 29.2 pg/mL), but still higher than normal group (361.8 +/- 47.1 pg/mL, 34.2 +/- 15.1 pg/mL) and lower than positive group (418.1 +/- 42.5 pg/mL, 90.2 +/- 17.8 pg/mL). Especially, when the concentration of SCP was 125 mu g/mL, the contents of IL-6 (431.1 +/- 43.3 pg/mL, 401.7 +/- 55.7 pg/mL) and IL-12 (63.2 +/- 12.3 pg/mL, 52.3 +/- 8.7 pg/mL) were lowest. Discussion and conclusion: These findings demonstrate that SCP have excellent anti-RA activities and thus have great potential as a drug for treating RA diseases.
引用
收藏
页码:1567 / 1572
页数:6
相关论文
共 50 条
  • [1] Synthesis of Epoxyisoprostanes: Effects in Reducing Secretion of Pro-inflammatory Cytokines IL-6 and IL-12
    Egger, Julian
    Bretscher, Peter
    Freigang, Stefan
    Kopf, Manfred
    Carreira, Erick M.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2013, 52 (20) : 5382 - 5385
  • [2] IL-12, IL-6 and IFN-γ production by lymphocytes of pregnant women with rheumatoid arthritis remission during pregnancy
    Tchórzewski, H
    Krasomski, G
    Biesiada, L
    Glowacka, E
    Banasik, M
    Lewkowicz, P
    MEDIATORS OF INFLAMMATION, 2000, 9 (06) : 289 - 293
  • [3] IL-6 and IL-21 in Rheumatoid Arthritis
    Carbone, Gustavo
    Wilson, Augusta
    Diehl, Sean
    Bunn, Janice
    Cooper, Sheldon
    Rincon, Mercedes
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S505 - S505
  • [4] Pathogenic roles of IL-6 and IL-6 blocking therapy on rheumatoid arthritis
    Yoshizaki, K
    Nishimoto, N
    Miyasaka, N
    Yamamoto, K
    Kawai, S
    Takeuchi, T
    Kishimoto, T
    ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 3) : S42 - S42
  • [5] Pathogenic roles of IL-6 and IL-6 blocking therapy on rheumatoid arthritis
    K Yoshizaki
    N Nishimoto
    N Miyasaka
    K Yamamoto
    S Kawai
    T Takeuchi
    T Kishimoto
    Arthritis Res Ther, 5
  • [6] Systems biology of IL-6, IL-12 family cytokines
    Dittrich, Anna
    Hessenkemper, Wiebke
    Schaper, Fred
    CYTOKINE & GROWTH FACTOR REVIEWS, 2015, 26 (05) : 595 - 602
  • [7] Association of Cytokine IL-17, IL-4, IL-6, and IL-12 Gene Polymorphisms in Rheumatoid Arthritis Patients in a Tertiary Care Hospital in Bangladesh
    Jahan, Taskin
    Saleh, Ahmed Abu
    Anwar, Shaheda
    INTERNATIONAL JOURNAL OF RHEUMATOLOGY, 2024, 2024
  • [8] EFFECTS OF IL-6 RECEPTOR INHIBITION THERAPY ON THE SERUM LEVELS OF IL-33 AND IL-6 IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Choi, I. A.
    Lee, S. J.
    Park, W.
    Park, S. H.
    Shim, S. -C.
    Baek, H. J.
    Yoo, D. -H.
    Kim, H. A.
    Lee, S. K.
    Lee, Y. J.
    Park, Y. E.
    Cha, H. -S.
    Lee, E. Y.
    Lee, E. B.
    Song, Y. W.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 456 - 456
  • [9] Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference?
    Ali Berkant Avci
    Eugen Feist
    Gerd Rüdiger Burmester
    BioDrugs, 2018, 32 : 531 - 546
  • [10] Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?
    Avci, Ali Berkant
    Feist, Eugen
    Burmester, Gerd Ruediger
    BIODRUGS, 2018, 32 (06) : 531 - 546